Sonio Announces Top Maternal-Fetal Medicine Physician as Scientific Advisory Board Member
Femtech Ultrasound AI company Sonio adds a new expert to its team based in the United States following FDA Clearance
PARIS, FRANCE (APRIL 15th, 2024) – Sonio, the MedTech company specializing in women’s and children’s health, today announces the appointment of a new Scientific Advisory Board Member, Dr Yinka Oyelese, following their FDA Clearance in the US in 2023.
Currently serving as the Director of Obstetric Imaging at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, MA, Dr. Oyelese has over 37 years of experience in the medical field and specializes in high-risk pregnancies. Following training in Nigeria, he moved to London, where in the 1990s, he worked at St. George’s Hospital, London, under such ultrasound luminaries as Professors Stuart Campbell, Yves Ville, Tom Bourne, and Christoph Lees. He completed an OBGYN residency at Georgetown University Hospital and fellowship training in Maternal-Fetal Medicine at Robert Wood Johnson Medical School/Rutgers University. He regularly contributes to prominent journals and obstetrical textbooks and has authored editorials for The American Journal of Obstetrics & Gynecology and Ultrasound in Obstetrics & Gynecology. A trusted expert in the field, he lectures worldwide and is a peer reviewer for over 30 medical journals.
Dr. Oyelese joins current Sonio Scientific Advisory Board Members Pr. Rabih Chaoui, Pr. Richard Kwong Wai Choy and Pr. Mark D. Kilby are each medical leaders in their respective focuses.
Dr. Yinka Oyelese says “AI represents a transformative leap forward in ultrasound technology, with immense potential to enhance the quality, efficiency, and convenience of prenatal ultrasound. It dramatically expands the capabilities of obstetric ultrasound, with promising applications poised to benefit patients, sonographers, and physicians alike. I am thrilled to embark on this pioneering journey in partnership with Sonio, as we navigate the exciting possibilities this innovation holds.”
Celia Amabile, Head of Clinical at Sonio, says, “We are thrilled to announce our collaboration with Dr. Oyelese and welcome his expertise in US clinical practices to the Sonio Scientific Advisory Board. We are eager to share insights on the future challenges of prenatal ultrasound diagnosis with maternal healthcare providers across America. Together, we hope to share how AI can be leveraged for healthcare professionals of all experience levels.
Together, Sonio and Dr. Oyelese plan to make maternal healthcare more accessible to all women across the US. With over 20 years of experience as a leader in
obstetric and gynecological ultrasound, Dr. Oyelese will lend his extensive expertise to the Sonio team. Their goal is to introduce revolutionary technology into the maternal healthcare sector, aiming to transform and enhance the quality of care provided to mothers across the nation.
About Sonio:
Sonio is a highly customizable workflow and practice management solution powered by AI for automation, efficiency and quality control. “Sonio AI-enhanced¹ software empowers ultrasound practitioners and readers. Sonio assists them in performing every prenatal examination to their highest quality standards, ensuring the completeness of each examination, streamlining their workflow, and in prenatal diagnosis. Sonio is based on over five years of research and collaboration between leading experts in fetal medicine and AI.
¹AI-enhancement is provided by FDA 510(k) cleared Sonio Detect product and through Sonio Expert”
To learn more about Sonio, visit our website https://sonio.ai/us/
